June 27, 2023

South San Francisco, CA, June 26, 2023 – Presidio Medical, Inc., a global clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, announced the close of a $72 million Series C funding round led by Deerfield Management, existing investors Invus Opportunities and Action Potential Venture Capital, and joined by ShangBay Capital. Proceeds will be used to expand the team, scale manufacturing, and conduct long-term, pivotal clinical studies of Presidio’s unique ULF™ SCS system. FLG partner Mark Murray assisted.

Full press release is here.